We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > cystic fibrosis drug

News List

European approval for paediatric cystic fibrosis drug europeanpharmaceuticalreview
January 24, 2019
A paediatric treatment for 2 to 5 year olds has been approved by the European Commission to treat children with the most common form of cystic fibrosis…
EU label for Vertex's cystic fibrosis drug Orkambi expanded again to include even younger children firstwordpharma
January 22, 2019
Orkambi was initially approved in Europe in 2015 for patients with CF ages 12 years and older who have two copies of the F508del mutation and was later expanded to include children ages six to 11 years.
Proteostasis Therapeutics receives FDA approval for Cystic Fibrosis drug biospectrumasia
March 19, 2018
The FDA Office of Orphan Products Development grants Orphan Drug Designation to novel drugs or biologics that are intended for the treatment of rare diseases or conditions affecting fewer than 200,000 patients in the United States.